Topical ocular administration of progesterone decreases photoreceptor cell death in Retinal Degeneration Slow (rds) mice

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorAlambiaga Caravaca, Adrián Miguel
dc.contributor.authorCantó Catalá, Antolín
dc.contributor.authorRodilla Alama, Vicente
dc.contributor.authorLópez Castellano, Alicia
dc.contributor.authorMiranda Sanz, María
dc.contributor.otherProducción Científica UCH 2022
dc.contributor.otherUCH. Departamento de Ciencias Biomédicas
dc.contributor.otherUCH. Departamento de Farmacia
dc.date2022
dc.date.accessioned2023-04-01T04:00:18Z
dc.date.available2023-04-01T04:00:18Z
dc.date.issued2022-03-09
dc.descriptionEste artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/1424-8247/15/3/328
dc.descriptionEste artículo pertenece al número especial "Advances in Ocular Pharmacology".
dc.description.abstractRetinitis pigmentosa (RP) is an inherited eye disorder which triggers a cascade of retinal disorders leading to photoreceptor cell death and for which there is currently no effective treatment. The purpose of this research was to study whether ocular administration of a solution of progesterone (PG) in -cyclodextrins (CD) could delay photoreceptor cell death and counteract the gliosis process in an animal model of RP (rds mice). The possible effect of PG reaching the contralateral eye through the circulatory system was also evaluated. Finally, this research discusses and evaluates the diffusion of the drug from possible topical formulations for ocular administration of PG. A group of rds mice received one drop of a solution of PG in CD every 12 h for 10 days to the left eye, while the right eye was left untreated. Another group of rds mice (control) received the drug vehicle (PBS) on the left eye and, again, the right eye was left untreated. Once the treatment was finished on postnatal day 21, the animals were euthanized and histological immunofluorescence studies (TUNEL, GFAP, and DAPI staining) were carried out. Our results showed that the administration of a solution of PG in CD (CD-PG) as drops significantly decreased cell death and inflammation in the retina of the PG-treated eyes of rds mice. No effect was seen in the contralateral eye from PG that may have entered systemic circulation. In conclusion, CD-PG applied topically as drops to the eye decreases photoreceptor cell death in the early stages of RP, delaying vision loss and decreasing gliosis.
dc.formatapplication/pdf
dc.identifier.citationAlambiaga-Caravaca, A. M., Cantó, A., Rodilla, V., Miranda, M. & López-Castellano, A. (2022). Topical ocular administration of progesterone decreases photoreceptor cell death in Retinal Degeneration Slow (rds) mice. Pharmaceuticals, vol. 15, i. 3 (09 mar.), art. 328. DOI: https://doi.org/10.3390/ph15030328
dc.identifier.doihttps://doi.org/10.3390/ph15030328
dc.identifier.issn1424-8247 (Electrónico)
dc.identifier.urihttp://hdl.handle.net/10637/14184
dc.languagees
dc.language.isoen
dc.publisherMDPI
dc.relationEste artículo de investigación ha sido financiado gracias a una beca predoctoral dada a Adrián M. Alambiaga Caravaca a través de “Ayudas a la formación de Jóvenes Investigadores CEU-SANTANDER 20/21” y ha sido financiado por dos becas "SAF2017-86980-R” y “SANTANDER-CEU FUSP-BS-PPC19-8166C64B”. Mientras que, Antolín Cantó fue beneficiario de otra beca predoctoral (ACIF 199/2019).
dc.relationUCH. Financiación Universidad
dc.relation.ispartofPharmaceuticals, vol. 15, i. 3 (09 mar. 2022)
dc.relation.projectIDSAF2017-86980-R
dc.relation.projectIDSANTANDER-CEU FUSP-BS-PPC19-8166C64B
dc.relation.projectIDACIF 199/2019
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectProgesterona - Uso terapéutico.
dc.subjectRetinitis pigmentaria - Tratamiento.
dc.subjectRetinitis pigmentosa - Treatment.
dc.subjectProgesterone - Therapeutic use.
dc.titleTopical ocular administration of progesterone decreases photoreceptor cell death in Retinal Degeneration Slow (rds) mice
dc.typeArtículo
dspace.entity.typePublicationes
relation.isAuthorOfPublicatione36a0fd5-6bd6-4eb4-8155-f1dd017135c2
relation.isAuthorOfPublicationb1c460ae-17f0-4260-b073-47506721536c
relation.isAuthorOfPublicationb996c064-4a2e-4a1f-bf71-abdd9d0219aa
relation.isAuthorOfPublicationf8d3d1a6-1612-41de-b48e-2c5e6f3c4bec
relation.isAuthorOfPublication.latestForDiscoverye36a0fd5-6bd6-4eb4-8155-f1dd017135c2

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Topical_Alambiaga_PHARMACEUTICALS_2022.pdf
Size:
1.41 MB
Format:
Adobe Portable Document Format

Collections